ライフサイエンスコーパス: aripiprazole

1 :1:1 ratio) to placebo or 10 or 30 mg/day of aripiprazole.

2 speridone and for PANSS negative scores with aripiprazole.

3 eeks of treatment with either risperidone or aripiprazole.

4 treatment with risperidone, paliperidone, or aripiprazole.

5 the atypical APDs olanzapine (1.0 mg/kg) or aripiprazole (0.3 mg/kg) significantly potentiated the e

6 modification of the scaffold represented by aripiprazole (1), we discovered UNC9975 (2), UNC0006 (3)

7 Aripiprazole (20 and 30 mg/d) and risperidone (6 mg/d) w

8 tients in an acute manic or mixed episode to aripiprazole, 30 mg/day (reduced to 15 mg/day if needed

9 tematic review (total n=949, amisulpride=20, aripiprazole=8, chlorpromazine=13, haloperidol=316, intr

10 all timepoints was significantly higher for aripiprazole (97.1%) than for quetiapine-ER (89.2%; p=0.

11 by extensively exploring multiple regions of aripiprazole, a balanced D2R agonist.

12 authors compared the efficacy and safety of aripiprazole, a novel antipsychotic, to placebo for trea

13 ripiprazole), sedation (quetiapine, OFC, and aripiprazole), abnormal metabolic laboratory results (qu

14 HOMA-IR group difference at week 12 favoured aripiprazole (adjusted mean log-transformed group differ

15 Aripiprazole, an AAP considered metabolically sparing, i

16 Eleven patients were treated with aripiprazole and 13 patients were treated with risperido

17 Remission occurred in 40 (43%) who received aripiprazole and 26 (29%) who received placebo.

18 axine hydrochloride monotherapy, 91 received aripiprazole and 90 received placebo.

19 ability of the combination of olanzapine or aripiprazole and DVX to enhance ACh efflux in the HIP or

20 Novel dopamine receptor antagonists aripiprazole and ecopipam have shown potential efficacy

21 d with 50% reduced odds of remission in both aripiprazole and placebo arms.

22 nts did not differ significantly between the aripiprazole and placebo groups.

23 here were no significant differences between aripiprazole and placebo in mean change from baseline in

24 ail Making Test scaled score of less than 7, aripiprazole and placebo were equally efficacious (OR, 0

25 ealthy males received either single doses of aripiprazole and risperidone (n=28), amisulpride and lor

26 k 1 for PANSS total and positive scores with aripiprazole and risperidone and for PANSS negative scor

27 Aripiprazole and risperidone groups showed a similar low

28 ural hybridization of the antipsychotic drug aripiprazole and the heterocyclic catecholamine surrogat

29 n may respond favorably to augmentation with aripiprazole and thus may help to personalize treatment.

30 anzapine), fatigue, sedation, akathisia (for aripiprazole), and extrapyramidal symptoms.

31 nd the D2-selective ligands methylspiperone, aripiprazole, and its congener OPC4392 [7-[3-(4-(2,3-dim

32 Like methylspiperone, aripiprazole, and OPC4392, the two D4-selective 1,4-DAPs

33 bes systematic evaluation of the efficacy of aripiprazole, and parent training combined with risperid

34 nd clinical ADR profiles of methylphenidate, aripiprazole, and risperidone, and of kinase drugs targe

35 edications, including the DA partial agonist aripiprazole (APZ), have been inconsistent, suggesting t

36 gene, identified the atypical antipsychotic aripiprazole as one of the hits.

37 otypical atypical APD, clozapine, as well as aripiprazole, asenapine, iloperidone, lurasidone, olanza

38 Akathisia was more common with aripiprazole at week 2 (observed in 34 [60%] of 57 patie

39 ; or augment with an atypical antipsychotic, aripiprazole (augment-aripiprazole group, n = 505) for 1

40 eline set shifting moderated the efficacy of aripiprazole augmentation (odds ratio [OR], 1.66 [95% CI

41 nd Canada to test the efficacy and safety of aripiprazole augmentation for adults aged older than 60

42 up to a 12-week randomized clinical trial of aripiprazole augmentation for first-line treatment-resis

43 dding a second treatment (adding quetiapine, aripiprazole, buspirone alpha2delta ligand agents) is re

44 Mean prolactin levels decreased with aripiprazole but significantly increased 5-fold with ris

45 psychotics including haloperidol, clozapine, aripiprazole, chlorpromazine, quetiapine, olanzapine, ri

46 At the end of the study, both aripiprazole doses showed statistically significant diff

47 a lower remission rate but did not moderate aripiprazole efficacy; each standard deviation greater a

48 acute efficacy, safety, and tolerability of aripiprazole for adolescents with schizophrenia.

49 (valdecoxib for myocardial infarction (MI), aripiprazole for MI, and telithromycin for acute liver f

50 ect size and adverse effects associated with aripiprazole, further analysis including cost-effectiven

51 Response was greater for the augment-aripiprazole group (74.3%) than for either the switch gr

52 itch group [n = 124] vs 16.6% in the augment-aripiprazole group [n = 84]; and 22.5% in augment-buprop

53 A greater proportion of participants in the aripiprazole group achieved remission than did those in

54 e events occurring in more than 5% of either aripiprazole group and with a combined incidence at leas

55 The augment-aripiprazole group exceeded the switch group in remissio

56 Adverse effects more frequent in the augment-aripiprazole group included somnolence, akathisia, and w

57 tiapine-ER group vs 52 [91%] patients in the aripiprazole group), increased duration of sleep (47 [92

58 typical antipsychotic, aripiprazole (augment-aripiprazole group, n = 505) for 12 weeks (acute treatme

59 n group, and 28.9% (n = 146) for the augment-aripiprazole group.

60 Aripiprazole had significantly greater efficacy than pla

61 or agonists (e.g., terguride, preclamol, and aripiprazole) have antagonist-like effects at normosensi

62 s for eight second-generation antipsychotics-aripiprazole, iloperidone, olanzapine, paliperidone, que

63 ] of 48, and 34 [72%] of 47 patients and for aripiprazole in 49 [89%] of 55, 52 [96%] of 54, and 44 [

64 eeks of treatment with either risperidone or aripiprazole in a double-blind randomized clinical trial

65 pine-extended release (quetiapine-ER) versus aripiprazole in children and adolescents with first-epis

66 d-to-head comparison of quetiapine-ER versus aripiprazole in early-onset psychosis showed no signific

67 ed the efficacy, safety, and tolerability of aripiprazole in patients with acute exacerbation of schi

68 Aripiprazole increased longevity in a Drosophila model o

69 Aripiprazole increased PPI in low PPI gaters, whereas mo

70 mazine verus clozapine or haloperidol versus aripiprazole,increased incidence of the metabolic syndro

71 Aripiprazole is a dopamine D2 receptor partial agonist w

72 Aripiprazole is a dopamine partial agonist approved for

73 We aimed to assess whether aripiprazole is associated with a higher probability of

74 a first-line antidepressant, the addition of aripiprazole is effective in achieving and sustaining re

75 Aripiprazole is effective, safe, and well tolerated for

76 The dopamine partial agonist aripiprazole is increasingly used to treat pathologies f

77 Switching to aripiprazole led to improvement of non-HDL cholesterol l

78 New prescriptions of aripiprazole (lower metabolic risk) increased during the

79 Previously, we showed that aripiprazole may protect motivational function by preser

80 The aripiprazole-mediated decrease in ATXN3 abundance may re

81 cated GTS patients, this was not the case in aripiprazole-medicated GTS patients.

82 er consisting of patients who were receiving aripiprazole monotherapy, and to healthy subjects.

83 , and by 4.4 kg (95% CI, 3.7 to 5.2 kg) with aripiprazole (n = 41) compared with the minimal weight c

84 randomly assigned to quetiapine-ER (n=55) or aripiprazole (n=58).

85 did not remit and were randomly assigned to aripiprazole (n=91) or placebo (n=90).

86 ignificant effects on remission, as follows: aripiprazole (odds ratio [OR], 2.01; 95% CI, 1.48-2.73),

87 dds ratio: 1.26, 95% CI: 1.14-1.39), but not aripiprazole (odds ratio: 1.19, 95% CI: 0.94-1.52) was a

88 eness of lamotrigine, topiramate, valproate, aripiprazole, olanzapine, and omega-3 fatty acid supplem

89 ranging from 0.12 and 0.20 were observed for aripiprazole, olanzapine, and risperidone.

90 cally significant benefits were observed for aripiprazole, olanzapine, and risperidone.

91 Treatment with aripiprazole, olanzapine, quetiapine, or risperidone for

92 14, 2012) identified 14 short-term trials of aripiprazole, olanzapine/fluoxetine combination (OFC), q

93 To test the influence of aripiprazole on counterfactual learning, we administered

94 However, the effect of aripiprazole on more cognitive facets of human reinforce

95 bination of DVX, 50 mg/kg, and olanzapine or aripiprazole, on DA efflux in both the HIP and mPFC.

96 -end-point changes were not significant with aripiprazole or in the untreated comparison group.

97 Aripiprazole or placebo tablets were started at 2 mg dai

98 e (OR, 1.61; 95% CI, 0.99-2.64; P = .06) and aripiprazole (OR, 1.58; 95% CI, 1.21-2.07; P = .001) but

99 icant effects on response rates, as follows: aripiprazole (OR, 2.07; 95% CI, 1.58-2.72; NNT, 7), OFC

100 hiatric disease, we administered olanzapine, aripiprazole, or placebo for 9 days to healthy subjects

101 5 [5.46] for quetiapine-ER, -6.21 [5.42] for aripiprazole; p=0.98), but decreased over time in both g

102 to 20 mg/d (n = 101) or 30 mg/d (n = 101) of aripiprazole, placebo (n = 103), or 6 mg/d of risperidon

103 Our results suggest that whereas aripiprazole preserves direct learning of action-outcome

104 Aripiprazole produced statistically significant mean imp

105 inistration of the high-affinity D2 agonist, aripiprazole, reduces not only functional downregulation

106 thisia was the most common adverse effect of aripiprazole (reported in 24 [26%] of 91 participants on

107 Aripiprazole represents a potentially promising therapeu

108 nd 0.2 kg for placebo and 10 mg and 30 mg of aripiprazole, respectively.

109 antidepressant treatment, augmentation with aripiprazole resulted in a statistically significant but

110 d with placebo, except for those assigned to aripiprazole (risk ratio [RR] 0.62, 95% credible interva

111 Aripiprazole, risperidone, and amisulpride increased P50

112 iapine with less akathisia than haloperidol, aripiprazole, risperidone, and olanzapine, but, again, e

113 ies focused on exploring four regions of the aripiprazole scaffold, which resulted in the discovery o

114 first G protein-biased D2R agonist from the aripiprazole scaffold.

115 several adverse events, including akathisia (aripiprazole), sedation (quetiapine, OFC, and aripiprazo

116 a] and change from preceding phase [mania]), aripiprazole separated from placebo by day 4.

117 ER (starting from 50 mg/day) or 20 mg/day of aripiprazole (starting from 2.5 mg/day).

118 e randomly assigned (1:1) to the addition of aripiprazole (target dose 10 mg [maximum 15 mg] daily) d

119 ompletion rate was significantly higher with aripiprazole than with placebo (42% versus 21%).

120 of remission were significantly higher with aripiprazole than with placebo (53% vs 28%; number neede

121 n contrast to the weak agonistic behavior of aripiprazole, these ligands are capable of effectively m

122 om olanzapine, quetiapine, or risperidone to aripiprazole to ameliorate metabolic risk factors for ca

123 (reported in 24 [26%] of 91 participants on aripiprazole vs 11 [12%] of 90 on placebo).

124 Compared with placebo, aripiprazole was also associated with more Parkinsonism

125 ere similar between groups, but switching to aripiprazole was associated with a higher rate of treatm

126 Aripiprazole was generally well tolerated.

127 t changes in body weight versus placebo, and aripiprazole was not associated with elevated serum prol

128 Both 10- and 30-mg/day doses of aripiprazole were superior to placebo in the acute treat

129 ial agonists at DA D2 receptors (D2Rs), like aripiprazole, were developed to simultaneously target bo

130 iated with more metabolic adverse events and aripiprazole with more initial akathisia and, unexpected

131 Pretreatment of olanzapine or aripiprazole with the selective serotonin 5-HT(1A) antag

132 cation (risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone, asenapine, iloperidone, or pa